Study Comparing Injection Methods of Niagen4 and NAD to Understand Absorption and Tolerability in Adults Aged 40 to 65

What this Trial Is About

Researchers are evaluating the subjective effects and tolerability of Niagen, a specialized form of vitamin B3 called nicotinamide riboside chloride, administered by injection in healthy adults aged 40 to 65. The study compares Niagen with NAD, an active comparator, using the same injection routes. The goal is to understand how these substances are absorbed and tolerated when given by different injection methods. Participants receive either 100mg of Niagen or NAD dissolved in 2ml of bacteriostatic water, administered via intramuscular IM, subcutaneous SQ, or intravenous push IVP injection. There are also placebo groups receiving just bacteriostatic water through the same injection methods. The study is randomized and double-blinded to compare the effects across these groups. During the study, participants will be monitored closely with assessments including pain and discomfort questionnaires one minute after injections. Blood tests for inflammation markers such as C-reactive protein, sedimentation rate, and plasma viscosity will be taken at baseline, 90 minutes post-injection, and on day 10. The study lasts for the duration needed to complete these assessments, with safety and tolerability as key focus points.

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+